New Cell Lines Cuts Down the Cost and Time in the Production of Flu Vaccine
...ique is very useful and is not time consuming when compared to the earlier procedure in which the virus strains were grown in fertilized chicken eggs. hepalife Technologies Inc., a biotechnology company based in Vancouver, has licensed the technology from MSU and plans to produce cell culture-based flu vaccin...HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
... BOSTON--(BUSINESS WIRE)--May 29, 2007 - hepalife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500...22-1.html.php) Protected by five issued patents, hepalife is developing production methods to make flu vacci... vaccine research: www.hepalife.com/media) ABOUT hepalife TECHNOLOGIES, INC. ...HepaLife's PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
... BOSTON--(BUSINESS WIRE)--Jun 25, 2007 - hepalife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: ... commented Mr. Frank Menzler, President and CEO of hepalife Technologies, Inc. "I'm especially pleased that ou.... (View HepaLife's April 30, 2007 press release: hepalife achieves major milestone in development of artific...Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
PASADENA, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC Bulletin Board: ABOS) today announced that it has sold all its rights and interest in its bioartificial liver system, HepatAssist, to HepaLife Technologies, Inc. (OTC Bulletin Board: HPLF), a Boston-based biotechnolog...